Page last updated: 2024-09-03

cholecystokinin 33 (10-20) and vasoactive intestinal peptide

cholecystokinin 33 (10-20) has been researched along with vasoactive intestinal peptide in 1 studies

Compound Research Comparison

Studies
(cholecystokinin 33 (10-20))
Trials
(cholecystokinin 33 (10-20))
Recent Studies (post-2010)
(cholecystokinin 33 (10-20))
Studies
(vasoactive intestinal peptide)
Trials
(vasoactive intestinal peptide)
Recent Studies (post-2010) (vasoactive intestinal peptide)
50010,8731231,221

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ahrén, B; Efendic, S; Sandberg, E; Tendler, D1

Other Studies

1 other study(ies) available for cholecystokinin 33 (10-20) and vasoactive intestinal peptide

ArticleYear
Cholecystokinin-33 potentiates and vasoactive intestinal polypeptide inhibits gastric inhibitory polypeptide--induced insulin secretion in the perfused rat pancreas.
    Acta endocrinologica, 1988, Volume: 117, Issue:4

    Topics: Animals; Cholecystokinin; Drug Interactions; Gastric Inhibitory Polypeptide; Glucose; Insulin; Insulin Secretion; Male; Pancreas; Peptide Fragments; Perfusion; Rats; Rats, Inbred Strains; Vasoactive Intestinal Peptide

1988